IRF1 and cancer: p21 was further shown to mediate IRF1’s ability to induce dose-dependent cell cycle arrest at the G1 phase in cancer cells, which was associated with reduced levels of CDC-2, CDK2, CDK4, cyclin B1, and cyclin E1 [33].